effect of Triphaladi Granules on Diabetes

A Clinico-experimental Study on Triphaladi Granules in Apathyanimittaja Prameha (Type II Diabetes Mellitus)

Status

Active, not recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2011/12/002195

Enrollment

Registered

2011-12-05

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients suffering from Prameha ( Diabetes Mellitus )

Interventions

Intervention1: Triphaladi Granules: 5 g BD with Lukewarm water along with exercise and Pathya for 2 months Control Intervention1: Any allopathic medicine: dose as recommended by modern physician along

Eligibility

Inclusion criteria

Inclusion criteria: Known patient of Type II Diabetes mellitus, and also the patients preliminarily diagnosed Type II Diabetes mellitus on the basis of signs and symptoms of the disease will be confirmed by FBS and PPBS and then will be included in study. Patients presenting with Type2 DM having , Random serum glucose level of greater than 200 mg/dl. Fasting Blood Sugar greater than 126 mg/dl Patients of Type2 Diabetes mellitus under Modern medication.

Exclusion criteria

Exclusion criteria: 1. Age below 30 years & above 70 years. 2.Patients of Sahaja Prameha and having bala and dhatukshaya (gestational diabetes mellitus) and Type I Diabetes mellitus. 3.Patient having any one of following condition. •Malignant and accelerated hypertensive •CVS disorder (CAD) •Pregnant woman and planning to be pregnant within six months •Lactating mother •Secondary Diabetes mellitus,Diabetic ketosis •CNS disorder e.g. encephalopathy •Patient under going regular treatment for any other severe illness and also patients suffering from Tuberculosis, Carcinoma and HIV positive patients. will be excluded for the present study including endocrinal disorders like, Thyrotoxicosis, Cushing Syndrome etc.

Design outcomes

Primary

Measure	Time frame
The efficacy of treatment will be assessed on the basis of relief in signs and symptoms. Evaluation of biochemical parameters such as FBS, PPBS in both groups along with Hematological, Urine routine and microscopic examination before and after the treatment. S. Insulin and Glycosulated haemoglobin before and after the treatment.(if possible ) Timepoint: At interval of one month and of two months the Evaluation of biochemical parameters such as FBS, PPBS in both groups along with Hematological, Urine routine and microscopic examination before and after the treatment. S. Insulin and Glycosulated haemoglobin before and after the treatment.(if possible ) and The efficacy of treatment will be assessed on the basis of relief in signs and symptoms.	—

Measure

Time frame

The efficacy of treatment will be assessed on the basis of relief in signs and symptoms. Evaluation of biochemical parameters such as FBS, PPBS in both groups along with Hematological, Urine routine and microscopic examination before and after the treatment. S. Insulin and Glycosulated haemoglobin before and after the treatment.(if possible ) Timepoint: At interval of one month and of two months the Evaluation of biochemical parameters such as FBS, PPBS in both groups along with Hematological, Urine routine and microscopic examination before and after the treatment. S. Insulin and Glycosulated haemoglobin before and after the treatment.(if possible ) and The efficacy of treatment will be assessed on the basis of relief in signs and symptoms.

—

Secondary

Measure	Time frame
exacerbation in signs and symptomsTimepoint: 4 weeks	—

Countries

India

Contacts

Public ContactProf HM Chandola

IPGTRA

drhmchandola@yahoo.com9426208877

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026